Traws Pharma, Inc. (NASDAQ:TRAW) Receives Average Recommendation of “Reduce” from Analysts

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have received an average rating of “Reduce” from the five analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $1.00.

Several equities research analysts have commented on TRAW shares. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Weiss Ratings cut shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. HC Wainwright reissued a “negative” rating and issued a $1.00 price objective on shares of Traws Pharma in a research report on Thursday, June 18th. Finally, Citigroup cut shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th.

Traws Pharma Price Performance

Shares of Traws Pharma stock opened at $0.47 on Tuesday. The firm has a market cap of $7.14 million, a price-to-earnings ratio of -0.28 and a beta of 1.57. The stock’s 50-day moving average is $0.89 and its 200-day moving average is $1.47. Traws Pharma has a one year low of $0.43 and a one year high of $3.27.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.39. On average, equities analysts expect that Traws Pharma will post -1.43 EPS for the current year.

Hedge Funds Weigh In On Traws Pharma

A number of large investors have recently modified their holdings of the business. State Street Corp acquired a new position in shares of Traws Pharma during the 4th quarter worth about $29,000. Two Sigma Investments LP increased its position in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the last quarter. XTX Topco Ltd increased its position in shares of Traws Pharma by 294.2% in the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Traws Pharma during the fourth quarter valued at approximately $56,000. Finally, Geode Capital Management LLC grew its stake in Traws Pharma by 41.9% in the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after purchasing an additional 18,213 shares in the last quarter. 7.95% of the stock is currently owned by institutional investors and hedge funds.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.